Stock listing

Frankfurt:IKAP Aurinia Pharmaceuticals Inc Aktie

German listing (Frankfurt) of Aurinia Pharmaceuticals Inc · home listing NASDAQ:AUPH

Follow Aurinia Pharmaceuticals Inc into a list and get an email when it puts out news.

Share price · FWB:IKAP

€14.82 EUR -0.21 (-1.4%)

Close on Oct 30, 2026

Day range
€14.82 – €15.17 EUROct 30, 2026
Market cap
€1.97B EURAt the close on Oct 30, 2026 · price × 133.1M shares outstanding
Aurinia Pharmaceuticals Inc logo

Prices by listing

ListingLastChangeVolumeOpenHighLowPrevious closePrice from
NASDAQ:AUPH · Home$16.65 USD-0.56 (-3.3%)960,798$16.76$17.04$16.48$17.21Close on Oct 30, 2026
Frankfurt:IKAP€14.82 EUR-0.215 (-1.4%)—€15.17€15.17€14.82€15.03Close on Oct 30, 2026
Ticker
Frankfurt:IKAP
Asset type
Stock
Exchange
Frankfurt
Currency
EUR

What changed lately

Calls

Replays

  • Aurinia Pharmaceuticals (NASDAQ:AUPH) Q4 2025 Earnings Call

    Thu, Feb 26, 2026 · 8:30 AM ET

    Watch Transcript

  • Aurinia Pharmaceuticals (NASDAQ:AUPH) Q3 2025 Earnings Call

    Tue, Nov 04, 2025 · 8:30 AM ET

    Watch Transcript

  • Aurinia Pharmaceuticals (NASDAQ:AUPH) Q2 2025 Earnings Call

    Thu, Jul 31, 2025 · 8:30 AM ET

    Watch Transcript

Latest news

Aurinia Pharmaceuticals Reports Financial Results for the Three and Nine Months Ended September 30, 2026 and Provides Update on Recent Business Progress

Oct 30, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three and Six Months Ended June 30, 2026 and Provides Update on Recent Business Progress

Aug 6, 2026

Aurinia Announces Initiation of PRESERVE, a Study Investigating the Combination of LUPKYNIS and Belimumab, Obinutuzumab or Anifrolumab in Patients with Lupus Nephritis

Jul 6, 2026

LUPKYNIS Associated with a Statistically Significant 53% Reduction in Risk of Renal-Related Event or Death

Jun 4, 2026

Aurinia Pharmaceuticals Completes Successful Tender Offer for Kezar Life Sciences

May 19, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three Months Ended March 31, 2026 and Provides Update on Recent Business Progress

May 7, 2026

Aurinia Pharmaceuticals to Acquire Kezar Life Sciences for $6.955 in Cash per Share Plus a Contingent Value Right

Mar 30, 2026

Aurinia Announces Management Transition

Mar 23, 2026

Aurinia Pharmaceuticals Reports Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provides Update on Recent Business Progress

Feb 26, 2026

Aurinia Pharmaceuticals to Report Financial Results for the Three and Twelve Months Ended December 31, 2025 and Provide Update on Recent Business Progress on February 26, 2026

Feb 19, 2026

All Aurinia Pharmaceuticals Inc news

Decks

Aurinia Pharmaceuticals Inc on 6ix

News releases
13 in the last 12 months · 202 in all · newest Oct 30, 2026 · oldest 2019
Calls
17 calls with a replay · 17 with a transcript · latest Feb 26, 2026
Decks
7 decks · latest October 2026

Where Aurinia Pharmaceuticals Inc is listed

ListingExchangeCountryCurrency
NASDAQ:AUPH · Home listingNASDAQUnited StatesUSD
gettex:IKAPgettexGermanyEUR
Lang & Schwarz:A1W7D4Lang & SchwarzGermanyEUR
LS Exchange:A1W7D4LS ExchangeGermanyEUR
BOATS:AUPHBOATSUnited StatesUSD
Frankfurt:IKAP · This pageFrankfurtGermanyEUR
LSE:0UJFLSEUnited KingdomCAD
Stuttgart:IKAPStuttgartGermanyEUR
Tradegate:IKAPTradegateGermanyEUR
Dusseldorf:IKAPDusseldorfGermanyEUR
Munich:IKAPMunichGermanyEUR

Log in to ask 6ix AI your own questions about Aurinia Pharmaceuticals Inc.